Stocks and Investing Stocks and Investing
Thu, June 1, 2023
Wed, May 31, 2023

Andrew Fein Reiterated (AMLX) at Strong Buy and Held Target at $50 on, May 31st, 2023


Published on 2024-10-28 04:06:39 - WOPRAI, Andrew Fein
  Print publication without navigation


Andrew Fein of HC Wainwright & Co., Reiterated "Amylyx Pharmaceuticals, Inc." (AMLX) at Strong Buy and Held Target at $50 on, May 31st, 2023.

Andrew has made no other calls on AMLX in the last 4 months.



There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 1 agrees with Andrew's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Chris Shibutani of "Goldman Sachs" Maintained at Hold with Increased Target to $47 on, Tuesday, March 14th, 2023


These are the ratings of the 2 analyists that currently disagree with Andrew


  • Graig Suvannavejh of "Mizuho" Maintained at Strong Buy with Decreased Target to $50 on, Monday, May 15th, 2023
  • Itay Michaeli of "Citigroup" Maintained at Strong Buy with Increased Target to $54 on, Tuesday, March 14th, 2023

Contributing Sources